InfectoPharm promotes clinical studies in accordance with the Good Clinical Practices (GCPs) Guidelines, in collaboration with medical specialists and microbiologists from hospitals and research institutes to offer patients and medical users drugs whose efficacy and safety are guaranteed over time. This attitude is particularly significant in the pediatric field, where the availability of drugs is still inadequate.

We are committed to opening new therapeutic avenues, for example in the treatment of cystic fibrosis or serious infections with problematic germs that do not respond to standard antibiotics.

InfectoPharm continues to invest in research and the study of its products even after they have been placed on the market, to ensure that the drugs are always adequate for the benefit of patients’ health.